Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5686017 | 0.81 | DRD2 (0.72) | DRD2DRD4DRD3TDP1RAB9A | |
| SCHEMBL2063136 | 0.81 | DRD2 (0.72) | DRD2DRD4DRD3TDP1RAB9A | |
| SCHEMBL17277367 | 0.80 | SMN1; SMN2 (0.51) | DRD2DRD4DRD3TDP1ADRB2 | |
| SCHEMBL17277514 | 0.80 | SMN1; SMN2 (0.51) | DRD2DRD4DRD3TDP1ADRB2 | |
| SCHEMBL27523668 | 0.80 | ADRB2 (0.50) | DRD2DRD4ADRB2ADRB1KMT2A | |
| Hydrochloric Acid SCHEMBL27537979 | 0.78 | ADRB2 (0.49) | ADRB2ADRB1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL28814341 | 0.78 | SLC2A1 (0.47) | DRD2DRD4ADRB2ADRB1KMT2A | |
| SCHEMBL19685914 | 0.77 | SCN4A (0.69) | ADRB2ADRB1 | |
| SCHEMBL3574069 | 0.77 | SMN1; SMN2 (0.53) | DRD2DRD4TDP1ADRB2ADRB1 | |
| SCHEMBL18295355 | 0.76 | ADRB2 (0.56) | ADRB2ADRB1KMT2AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728005-B2 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | DRD2 1532/4885DRD4 2154/4885DRD3 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.